The UK’s first venture capital fund devoted to “psychedelic healthcare” was launched last week and will invest in “revolutionary mind-altering medicines” to treat illnesses including depression, addiction, anxiety and inflamation.
The UK’s first venture capital fund devoted to “psychedelic healthcare” was launched last week and will invest in “revolutionary mind-altering medicines” to treat illnesses including depression, addiction, anxiety and inflamation.
A team of former JP Morgan executives have secured funding for the launch of a wealth management platform.
Morgan Stanley Investment Management (MSIM) has unveiled a sustainable bond fund for UK investors.
Lyxor Asset Management has joined forces with American firm Bridgewater Associates to roll out a multi-asset sustainability strategy.
AllianceBernstein has unveiled a strategy that it says aims to hugely lower the carbon footprint in MSCI World Index investments.
New York-based ETF provider Global X ETFs has entered the European market and made senior hires.
